A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study
PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment
56
Participants
Timeline
Start Date
November 14, 2017
Primary Completion Date
May 9, 2018
Study Completion Date
May 9, 2018
Conditions
Respiratory Syncytial Virus Infections
Interventions
DRUG
PC786
Repeat doses
DRUG
Placebo/vehicle
Repeat doses
Trial Locations (1)
E1 2AX
hVIVO Services Ltd, London
All Listed Sponsors
lead
Pulmocide Ltd
INDUSTRY
NCT03382431 - A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study | Biotech Hunter | Biotech Hunter